α发射体市场 - 全球产业规模、份额、趋势、机会和预测，按放射性核种类型（砹、镭、锕、铅、铋、其他）、按医疗应用、按地区和竞争细分，2020-2030 年预测

2024 年全球α发射体市场价值为 4.661 亿美元，预计在预测期内将实现强劲成长，到 2030 年的复合年增长率为 9.80%。全球α发射体市场是核医和放射治疗领域内的专业部门。它围绕着发射阿尔法放射性核种的生产、分布和应用展开，阿尔法放射性核种是发射阿尔法粒子的放射性同位素。这是由于疾病盛行率不断上升、癌症病例不断增加、人口老化不断加剧等原因造成的。例如，国际癌症研究机构 (IARC) 预测，到 2040 年，全球癌症负担将上升至 2,750 万新病例和 1,630 万癌症相关死亡病例，这主要是由于人口增长和老化造成的。此外，2022 年 8 月《辐射》杂誌上的一篇文章介绍了日本近畿大学一位科学家的研究，探索了镭-223 疗法对转移性去势抵抗性前列腺癌的最佳应用。研究表明，早期使用 Ra-223 可显着提高整体存活率 (OS)，凸显了在新型荷尔蒙或抗癌治疗之前使用 Ra-223 的潜在优势。阿尔法发射体因其独特的特性在医疗、工业和能源领域占据了重要地位，市场正在经历显着的成长和创新。由于释放了由两个质子和两个中子组成的阿尔法粒子。这些粒子带电性很强，在组织中的传播范围很短，因此可有效局部治疗。阿尔法辐射效力强大，能够精确地损害和摧毁癌细胞，同时保护附近的健康组织。

主要市场驱动因素

核子医学需求不断成长

主要市场挑战

监管障碍

主要市场趋势

标靶阿尔法粒子治疗的进展：

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第五章：全球α发射体市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依放射性核种类型（砹（At-211）、镭（Ra-223）、锕（Ac-225）、铅（Pb-212）、铋（Bi-212）、其他）
  • 依医疗应用（前列腺癌、骨转移、卵巢癌、胰臟癌、内分泌肿瘤、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美α发射体市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 加拿大
  • 墨西哥

第七章：欧洲α发射体市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 英国
  • 义大利
  • 法国
  • 西班牙

第 8 章：亚太地区α发射体市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 日本
  • 韩国
  • 澳洲

第 9 章：南美洲α发射体市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲α发射体市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式

第 11 章：2 个挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 合併与收购

第 13 章：全球α发射体市场：SWOT 分析

第 14 章：竞争格局

• Actinium Pharmaceutical Inc.
• Alpha Tau Medical Ltd
• Bayer AG
• Fusion Pharmaceuticals
• IBA Radiopharma Solutions
• RadioMedix Inc.
• Telix Pharmaceuticals Ltd
• Novartis International AG
• Isotopen Technologien Munchen AG (ITM)
• NorthStar Medical Radioisotopes

第 15 章：策略建议

第16章调查会社について・免责事项

Global Alpha Emitter Market Was valued at USD 466.10 million in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 9.80% through 2030. The Global Alpha Emitter Market is a specialized sector within the broader field of nuclear medicine and radiation therapy. It revolves around the production, distribution, and application of alpha-emitting radionuclides, which are radioactive isotopes emitting alpha particles. This is ascribed due to the growing disease prevalence, growing cancer cases, rising aging population, etc. For instance, the International Agency for Research on Cancer (IARC) projects that by 2040, the global cancer burden will rise to 27.5 million new cases and 16.3 million cancer-related deaths, largely due to population growth and aging. Additionally, an August 2022 article in the Radiation journal featured research by a Kindai University scientist in Japan exploring the optimal use of Radium-223 therapy for Metastatic Castration-Resistant Prostate Cancer. The study indicated that early administration of Ra-223 significantly improved overall survival (OS), highlighting potential advantages of using Ra-223 before novel hormonal or anticancer treatments. Alpha emitters have gained prominence in medical, industrial, and energy sectors due to their unique characteristics, and the market is experiencing notable growth and innovation. Due to the release of alpha particles, which consist of two protons and two neutrons. These particles are highly charged and have a short range in tissue, making them effective for localized therapy. Alpha radiation is potent, capable of damaging and destroying cancer cells with precision while sparing nearby healthy tissue.

Key Market Drivers

Growing Demand for Nuclear Medicine

One of the primary drivers of the Global Alpha Emitter Market is the increasing demand for nuclear medicine. Advances in medical science have revealed the efficacy of alpha emitters in targeted cancer therapy. Alpha particles are highly effective at killing cancer cells, making them a vital component of radiopharmaceuticals used in cancer treatment. The shift towards precision medicine is another key reason for the growing demand. Medical professionals are increasingly tailoring treatments to individual patients, and alpha emitters offer a precise way to target cancerous cells while minimizing damage to healthy tissue. The global rise in cancer cases is a significant driver. As cancer incidence continues to increase, the demand for effective treatment options also grows. Alpha emitters provide a promising solution for certain types of cancers that are challenging to treat through conventional methods. Ongoing clinical trials and research efforts are further fueling demand. Pharmaceutical companies and research institutions are investing heavily in the development of new alpha-emitting radiopharmaceuticals, expanding the range of treatable conditions. Increasing patient awareness and advocacy groups' efforts have contributed to the demand for nuclear medicine. Patients and their families are seeking out cutting-edge treatments, and alpha emitter-based therapies are becoming more accessible and sought after.

Key Market Challenges

Regulatory Hurdles

Regulatory hurdles, such as stringent licensing and safety regulations, can significantly impede the growth of the Global Alpha Emitter Market. Governments and regulatory bodies closely monitor the use and transport of radioactive materials, including alpha emitters, due to safety concerns. This leads to lengthy approval processes and strict compliance requirements. The highly radioactive nature of alpha emitters necessitates rigorous oversight to prevent accidents and ensure public safety. However, the complexity and stringency of regulatory processes can slow down the development and commercialization of alpha-emitting products. Companies may face delays and increased costs in navigating the regulatory landscape, hindering market growth.

Key Market Trends

Advancements in Targeted Alpha-Particle Therapy:

A significant trend in the Global Alpha Emitter Market is the continuous advancements in targeted alpha-particle therapy. This therapy involves the use of alpha-emitting radiopharmaceuticals to precisely target and destroy cancer cells while sparing healthy tissue. Recent research and development efforts have led to the creation of novel alpha-emitting compounds that are more effective and have reduced side effects. This trend is driven by the increasing focus on personalized medicine in oncology. Healthcare providers and pharmaceutical companies are investing in research to develop alpha emitters that can be tailored to a patient's specific cancer type and genetic profile. As a result, targeted alpha-particle therapy is gaining prominence as a promising and minimally invasive treatment option for various cancers, including prostate, bone, and pancreatic cancer.

Key Market Players

• Actinium Pharmaceutical Inc.
• Alpha Tau Medical Ltd
• Bayer AG
• Fusion Pharmaceuticals
• IBA Radiopharma Solutions
• RadioMedix Inc.
• Telix Pharmaceuticals Ltd
• Novartis International AG
• Isotopen Technologien Munchen AG(ITM)
• NorthStar Medical Radioisotopes

Report Scope:

In this report, the Global Alpha Emitter Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Alpha Emitter Market, By Type of Radionuclide:

• Astatine (At-211)
• Radium (Ra-223)
• Actinium (Ac-225)
• Lead (Pb-212)
• Bismuth (Bi-212)
• Other

Alpha Emitter Market, By Medical Application:

• Prostate Cancer
• Bone Metastasis
• Ovarian Cancer
• Pancreatic Cancer
• Endocrine Tumors
• Other

Alpha Emitter Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Alpha Emitter Market.

Available Customizations:

Global Alpha Emitter market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Alpha Emitter Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type of Radionuclide (Astatine (At-211), Radium (Ra-223), Actinium (Ac-225), Lead (Pb-212), Bismuth (Bi-212), Other)
  • 5.2.2. By Medical Application (Prostate Cancer, Bone Metastasis, Ovarian Cancer, Pancreatic Cancer, Endocrine Tumors, Other)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Alpha Emitter Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type of Radionuclide
  • 6.2.2. By Medical Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Alpha Emitter Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type of Radionuclide
      • 6.3.1.2.2. By Medical Application
  • 6.3.2. Canada Alpha Emitter Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type of Radionuclide
      • 6.3.2.2.2. By Medical Application
  • 6.3.3. Mexico Alpha Emitter Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type of Radionuclide
      • 6.3.3.2.2. By Medical Application

7. Europe Alpha Emitter Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type of Radionuclide
  • 7.2.2. By Medical Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Alpha Emitter Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type of Radionuclide
      • 7.3.1.2.2. By Medical Application
  • 7.3.2. United Kingdom Alpha Emitter Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type of Radionuclide
      • 7.3.2.2.2. By Medical Application
  • 7.3.3. Italy Alpha Emitter Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Type of Radionuclide
      • 7.3.3.2.2. By Medical Application
  • 7.3.4. France Alpha Emitter Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type of Radionuclide
      • 7.3.4.2.2. By Medical Application
  • 7.3.5. Spain Alpha Emitter Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type of Radionuclide
      • 7.3.5.2.2. By Medical Application

8. Asia-Pacific Alpha Emitter Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type of Radionuclide
  • 8.2.2. By Medical Application
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Alpha Emitter Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type of Radionuclide
      • 8.3.1.2.2. By Medical Application
  • 8.3.2. India Alpha Emitter Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type of Radionuclide
      • 8.3.2.2.2. By Medical Application
  • 8.3.3. Japan Alpha Emitter Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type of Radionuclide
      • 8.3.3.2.2. By Medical Application
  • 8.3.4. South Korea Alpha Emitter Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type of Radionuclide
      • 8.3.4.2.2. By Medical Application
  • 8.3.5. Australia Alpha Emitter Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type of Radionuclide
      • 8.3.5.2.2. By Medical Application

9. South America Alpha Emitter Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type of Radionuclide
  • 9.2.2. By Medical Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Alpha Emitter Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type of Radionuclide
      • 9.3.1.2.2. By Medical Application
  • 9.3.2. Argentina Alpha Emitter Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type of Radionuclide
      • 9.3.2.2.2. By Medical Application
  • 9.3.3. Colombia Alpha Emitter Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type of Radionuclide
      • 9.3.3.2.2. By Medical Application

10. Middle East and Africa Alpha Emitter Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type of Radionuclide
  • 10.2.2. By Medical Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Alpha Emitter Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type of Radionuclide
      • 10.3.1.2.2. By Medical Application
  • 10.3.2. Saudi Arabia Alpha Emitter Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type of Radionuclide
      • 10.3.2.2.2. By Medical Application
  • 10.3.3. UAE Alpha Emitter Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type of Radionuclide
      • 10.3.3.2.2. By Medical Application

11. Market Dynamics

• 11.1. Drivers

11.2 Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Alpha Emitter Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Actinium Pharmaceutical Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Medical Application Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Key Personnel
  • 14.1.5. SWOT Analysis
• 14.2. Alpha Tau Medical Ltd
• 14.3. Bayer AG
• 14.4. Fusion Pharmaceuticals
• 14.5. IBA Radiopharma Solutions
• 14.6. RadioMedix Inc.
• 14.7. Telix Pharmaceuticals Ltd
• 14.8. Novartis International AG
• 14.9. Isotopen Technologien Munchen AG (ITM)
• 14.10. NorthStar Medical Radioisotopes

15. Strategic Recommendations

16. About Us & Disclaimer